Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias.

Schmitt MW, Pritchard JR, Leighow SM, Aminov BI, Beppu L, Kim DS, Hodgson JG, Rivera VM, Loeb LA, Radich JP.

Clin Cancer Res. 2018 Nov 1;24(21):5321-5334. doi: 10.1158/1078-0432.CCR-18-0167. Epub 2018 Jul 24.

PMID:
30042204
2.

Trade-offs between seed and leaf size (seed-phytomer-leaf theory): functional glue linking regenerative with life history strategies … and taxonomy with ecology?

Hodgson JG, Santini BA, Montserrat Marti G, Royo Pla F, Jones G, Bogaard A, Charles M, Font X, Ater M, Taleb A, Poschlod P, Hmimsa Y, Palmer C, Wilson PJ, Band SR, Styring A, Diffey C, Green L, Nitsch E, Stroud E, Romo-Díez A, de Torres Espuny L, Warham G.

Ann Bot. 2017 Nov 10;120(5):633-652. doi: 10.1093/aob/mcx084.

3.

The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.

Parker WT, Yeung DT, Yeoman AL, Altamura HK, Jamison BA, Field CR, Hodgson JG, Lustgarten S, Rivera VM, Hughes TP, Branford S.

Blood. 2016 Apr 14;127(15):1870-80. doi: 10.1182/blood-2015-09-666214. Epub 2016 Jan 14.

4.

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.

Deininger MW, Hodgson JG, Shah NP, Cortes JE, Kim DW, Nicolini FE, Talpaz M, Baccarani M, Müller MC, Li J, Parker WT, Lustgarten S, Clackson T, Haluska FG, Guilhot F, Kantarjian HM, Soverini S, Hochhaus A, Hughes TP, Rivera VM, Branford S.

Blood. 2016 Feb 11;127(6):703-12. doi: 10.1182/blood-2015-08-660977. Epub 2015 Nov 24.

5.

An evolutionary perspective on leaf economics: phylogenetics of leaf mass per area in vascular plants.

Flores O, Garnier E, Wright IJ, Reich PB, Pierce S, Dìaz S, Pakeman RJ, Rusch GM, Bernard-Verdier M, Testi B, Bakker JP, Bekker RM, Cerabolini BE, Ceriani RM, Cornu G, Cruz P, Delcamp M, Dolezal J, Eriksson O, Fayolle A, Freitas H, Golodets C, Gourlet-Fleury S, Hodgson JG, Brusa G, Kleyer M, Kunzmann D, Lavorel S, Papanastasis VP, Pérez-Harguindeguy N, Vendramini F, Weiher E.

Ecol Evol. 2014 Jul;4(14):2799-811. doi: 10.1002/ece3.1087. Epub 2014 Jul 1.

6.

Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer.

Budinska E, Popovici V, Tejpar S, D'Ario G, Lapique N, Sikora KO, Di Narzo AF, Yan P, Hodgson JG, Weinrich S, Bosman F, Roth A, Delorenzi M.

J Pathol. 2013 Sep;231(1):63-76. doi: 10.1002/path.4212. Epub 2013 Jul 8.

7.

Expression of miR-124 inhibits growth of medulloblastoma cells.

Silber J, Hashizume R, Felix T, Hariono S, Yu M, Berger MS, Huse JT, VandenBerg SR, James CD, Hodgson JG, Gupta N.

Neuro Oncol. 2013 Jan;15(1):83-90. doi: 10.1093/neuonc/nos281. Epub 2012 Nov 21.

8.

Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas.

Engler JR, Robinson AE, Smirnov I, Hodgson JG, Berger MS, Gupta N, James CD, Molinaro A, Phillips JJ.

PLoS One. 2012;7(8):e43339. doi: 10.1371/journal.pone.0043339. Epub 2012 Aug 22.

9.

A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations.

Xie T, D' Ario G, Lamb JR, Martin E, Wang K, Tejpar S, Delorenzi M, Bosman FT, Roth AD, Yan P, Bougel S, Di Narzo AF, Popovici V, Budinská E, Mao M, Weinrich SL, Rejto PA, Hodgson JG.

PLoS One. 2012;7(7):e42001. doi: 10.1371/journal.pone.0042001. Epub 2012 Jul 31.

10.

Targeted therapy for BRAFV600E malignant astrocytoma.

Nicolaides TP, Li H, Solomon DA, Hariono S, Hashizume R, Barkovich K, Baker SJ, Paugh BS, Jones C, Forshew T, Hindley GF, Hodgson JG, Kim JS, Rowitch DH, Weiss WA, Waldman TA, James CD.

Clin Cancer Res. 2011 Dec 15;17(24):7595-604. doi: 10.1158/1078-0432.CCR-11-1456. Epub 2011 Oct 28.

11.

Is leaf dry matter content a better predictor of soil fertility than specific leaf area?

Hodgson JG, Montserrat-Martí G, Charles M, Jones G, Wilson P, Shipley B, Sharafi M, Cerabolini BE, Cornelissen JH, Band SR, Bogard A, Castro-Díez P, Guerrero-Campo J, Palmer C, Pérez-Rontomé MC, Carter G, Hynd A, Romo-Díez A, de Torres Espuny L, Royo Pla F.

Ann Bot. 2011 Nov;108(7):1337-45. doi: 10.1093/aob/mcr225. Epub 2011 Sep 21.

12.

Stomatal vs. genome size in angiosperms: the somatic tail wagging the genomic dog?

Hodgson JG, Sharafi M, Jalili A, Díaz S, Montserrat-Martí G, Palmer C, Cerabolini B, Pierce S, Hamzehee B, Asri Y, Jamzad Z, Wilson P, Raven JA, Band SR, Basconcelo S, Bogard A, Carter G, Charles M, Castro-Díez P, Cornelissen JH, Funes G, Jones G, Khoshnevis M, Pérez-Harguindeguy N, Pérez-Rontomé MC, Shirvany FA, Vendramini F, Yazdani S, Abbas-Azimi R, Boustani S, Dehghan M, Guerrero-Campo J, Hynd A, Kowsary E, Kazemi-Saeed F, Siavash B, Villar-Salvador P, Craigie R, Naqinezhad A, Romo-Díez A, de Torres Espuny L, Simmons E.

Ann Bot. 2010 Apr;105(4):573-84. doi: 10.1093/aob/mcq011.

13.

A human-like senescence-associated secretory phenotype is conserved in mouse cells dependent on physiological oxygen.

Coppé JP, Patil CK, Rodier F, Krtolica A, Beauséjour CM, Parrinello S, Hodgson JG, Chin K, Desprez PY, Campisi J.

PLoS One. 2010 Feb 12;5(2):e9188. doi: 10.1371/journal.pone.0009188.

14.

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN; Cancer Genome Atlas Research Network.

Cancer Cell. 2010 Jan 19;17(1):98-110. doi: 10.1016/j.ccr.2009.12.020.

15.

Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging.

Barajas RF Jr, Hodgson JG, Chang JS, Vandenberg SR, Yeh RF, Parsa AT, McDermott MW, Berger MS, Dillon WP, Cha S.

Radiology. 2010 Feb;254(2):564-76. doi: 10.1148/radiol.09090663.

16.

Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.

Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS, Ji H, Gutmann DH, James CD.

Cancer Res. 2010 Jan 15;70(2):512-9. doi: 10.1158/0008-5472.CAN-09-1851. Epub 2010 Jan 12.

17.

Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality.

Collier LS, Adams DJ, Hackett CS, Bendzick LE, Akagi K, Davies MN, Diers MD, Rodriguez FJ, Bender AM, Tieu C, Matise I, Dupuy AJ, Copeland NG, Jenkins NA, Hodgson JG, Weiss WA, Jenkins RB, Largaespada DA.

Cancer Res. 2009 Nov 1;69(21):8429-37. doi: 10.1158/0008-5472.CAN-09-1760. Epub 2009 Oct 20.

18.

microRNAs in gliomas: small regulators of a big problem.

Silber J, James CD, Hodgson JG.

Neuromolecular Med. 2009;11(3):208-22. doi: 10.1007/s12017-009-8087-9. Review.

PMID:
19731102
19.

Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts.

Hodgson JG, Yeh RF, Ray A, Wang NJ, Smirnov I, Yu M, Hariono S, Silber J, Feiler HS, Gray JW, Spellman PT, Vandenberg SR, Berger MS, James CD.

Neuro Oncol. 2009 Oct;11(5):477-87. doi: 10.1215/15228517-2008-113. Epub 2009 Jan 12.

20.

Long-term resistance to simulated climate change in an infertile grassland.

Grime JP, Fridley JD, Askew AP, Thompson K, Hodgson JG, Bennett CR.

Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10028-32. doi: 10.1073/pnas.0711567105. Epub 2008 Jul 7.

21.

miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells.

Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James CD, Costello JF, Bergers G, Weiss WA, Alvarez-Buylla A, Hodgson JG.

BMC Med. 2008 Jun 24;6:14. doi: 10.1186/1741-7015-6-14.

22.

Mammary carcinoma behavior is programmed in the precancer stem cell.

Damonte P, Hodgson JG, Chen JQ, Young LJ, Cardiff RD, Borowsky AD.

Breast Cancer Res. 2008;10(3):R50. doi: 10.1186/bcr2104. Epub 2008 Jun 3.

23.

Copy number aberrations in mouse breast tumors reveal loci and genes important in tumorigenic receptor tyrosine kinase signaling.

Hodgson JG, Malek T, Bornstein S, Hariono S, Ginzinger DG, Muller WJ, Gray JW.

Cancer Res. 2005 Nov 1;65(21):9695-704.

24.

Specific leaf area and dry matter content estimate thickness in laminar leaves.

Vile D, Garnier E, Shipley B, Laurent G, Navas ML, Roumet C, Lavorel S, Díaz S, Hodgson JG, Lloret F, Midgley GF, Poorter H, Rutherford MC, Wilson PJ, Wright IJ.

Ann Bot. 2005 Nov;96(6):1129-36. Epub 2005 Sep 13.

25.

Syngeneic mouse mammary carcinoma cell lines: two closely related cell lines with divergent metastatic behavior.

Borowsky AD, Namba R, Young LJ, Hunter KW, Hodgson JG, Tepper CG, McGoldrick ET, Muller WJ, Cardiff RD, Gregg JP.

Clin Exp Metastasis. 2005;22(1):47-59.

PMID:
16132578
26.

Shared epigenetic mechanisms in human and mouse gliomas inactivate expression of the growth suppressor SLC5A8.

Hong C, Maunakea A, Jun P, Bollen AW, Hodgson JG, Goldenberg DD, Weiss WA, Costello JF.

Cancer Res. 2005 May 1;65(9):3617-23.

27.

Absence of telomerase and shortened telomeres have minimal effects on skin and pancreatic carcinogenesis elicited by viral oncogenes.

Argilla D, Chin K, Singh M, Hodgson JG, Bosenberg M, de Solórzano CO, Lockett S, DePinho RA, Gray J, Hanahan D.

Cancer Cell. 2004 Oct;6(4):373-85.

28.

Pancreatic insulinomas in multiple endocrine neoplasia, type I knockout mice can develop in the absence of chromosome instability or microsatellite instability.

Scacheri PC, Kennedy AL, Chin K, Miller MT, Hodgson JG, Gray JW, Marx SJ, Spiegel AM, Collins FS.

Cancer Res. 2004 Oct 1;64(19):7039-44.

29.

Array comparative genomic hybridization with cyanin cis-platinum-labeled DNAs.

Raap AK, van der Burg MJ, Knijnenburg J, Meershoek E, Rosenberg C, Gray JW, Wiegant J, Hodgson JG, Tanke HJ.

Biotechniques. 2004 Jul;37(1):130-4.

31.

Oncogene expression and genetic background influence the frequency of DNA copy number abnormalities in mouse pancreatic islet cell carcinomas.

Hager JH, Hodgson JG, Fridlyand J, Hariono S, Gray JW, Hanahan D.

Cancer Res. 2004 Apr 1;64(7):2406-10.

32.

TIMP-1 alters susceptibility to carcinogenesis.

Rhee JS, Diaz R, Korets L, Hodgson JG, Coussens LM.

Cancer Res. 2004 Feb 1;64(3):952-61.

33.

The role of p53 in suppression of KSHV cyclin-induced lymphomagenesis.

Verschuren EW, Hodgson JG, Gray JW, Kogan S, Jones N, Evan GI.

Cancer Res. 2004 Jan 15;64(2):581-9.

34.

Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors.

Hackett CS, Hodgson JG, Law ME, Fridlyand J, Osoegawa K, de Jong PJ, Nowak NJ, Pinkel D, Albertson DG, Jain A, Jenkins R, Gray JW, Weiss WA.

Cancer Res. 2003 Sep 1;63(17):5266-73.

35.

Genome amplification of chromosome 20 in breast cancer.

Hodgson JG, Chin K, Collins C, Gray JW.

Breast Cancer Res Treat. 2003 Apr;78(3):337-45. Review.

PMID:
12755492
36.

Induction of tumors in mice by genomic hypomethylation.

Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, Leonhardt H, Jaenisch R.

Science. 2003 Apr 18;300(5618):489-92.

37.

Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo.

Leavitt BR, Guttman JA, Hodgson JG, Kimel GH, Singaraja R, Vogl AW, Hayden MR.

Am J Hum Genet. 2001 Feb;68(2):313-24. Epub 2000 Dec 20.

38.

Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin.

Hackam AS, Hodgson JG, Singaraja R, Zhang T, Gan L, Gutekunst CA, Hersch SM, Hayden MR.

Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1047-55. Review.

39.

A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration.

Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li XJ, Stevens ME, Rosemond E, Roder JC, Phillips AG, Rubin EM, Hersch SM, Hayden MR.

Neuron. 1999 May;23(1):181-92.

40.

Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype.

Hodgson JG, Smith DJ, McCutcheon K, Koide HB, Nishiyama K, Dinulos MB, Stevens ME, Bissada N, Nasir J, Kanazawa I, Disteche CM, Rubin EM, Hayden MR.

Hum Mol Genet. 1996 Dec;5(12):1875-85.

PMID:
8968738
41.

Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme.

Kalchman MA, Graham RK, Xia G, Koide HB, Hodgson JG, Graham KC, Goldberg YP, Gietz RD, Pickart CM, Hayden MR.

J Biol Chem. 1996 Aug 9;271(32):19385-94.

Supplemental Content

Loading ...
Support Center